Stage IIIA lung adenocarcinoma: major pathological response after neoadjuvant immunochemotherapy, complicated by DILI/TEN

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: No lung molecular biomarkers reported

At 23 months after thoracoscopic left upper lobectomy, he was clinically stable with no evidence of tumor recurrence; severe postoperative DILI/TEN had improved after stopping the offending drug and intensive supportive treatment.

PubMed CentralRead more →

Recurrent lung adenocarcinoma with isolated pancreatic metastasis: Whipple resection after discordant tumor-origin testing

Patient Info: Anonymized, Female, 70+ | Stage Metastatic/Advanced

Biomarkers: Pancreatic lesion showed KRAS

Metastatic Site: mediastinal lymph node; pancreas

After prior lung surgery, adjuvant chemotherapy, and later chemoradiation for mediastinal nodal recurrence, an isolated pancreatic lesion was resected by Whipple procedure; post-Whipple recurrence status was not yet reported.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Megan's Survivor Story

Patient Info: Megan, Female, Under 40 | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Spine; chest lymph nodes; stomach lymph nodes

Stage IV ALK-positive non-small cell lung cancer responded dramatically to daily targeted therapy, with latest scans described as no evidence of disease while she continues long-term targeted therapy.

The Patient StoryRead more →

Small-cell lung cancer: envafolimab response complicated by immune-related diabetes, pneumonitis, and later submandibular progression

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: ProGRP and NSE were elevated at diagnosis. Tumor molecular biomarkers were not reported; diabetes antibodies were negative.

Metastatic Site: left submandibular region / adjacent lymph nodes

After initial partial response on envafolimab, carboplatin, etoposide, and thoracic radiotherapy, he developed immune-related diabetes, pneumonitis, and progressive left submandibular metastatic disease requiring iodine-125 seeds and later anlotinib.

PubMed CentralRead more →

Recurrent lung cancer with malignant airway compression: Dumon Y-stent improved breathing

Patient Info: Anonymized, Female

Dumon Y-shaped airway stenting restored airway patency, improved left-lung perfusion from 13% to 59%, and reduced dyspnea from MMRC grade 3 to grade 1.

PubMed CentralRead more →

Stage III EGFR Lung Cancer: Roxanne's Patient Story

Patient Info: Roxanne, Female, 40s | Stage III

Biomarkers: EGFR mutation

Roxanne had Stage III EGFR-mutated lung cancer after surgery found mediastinal lymph-node involvement. As of March 2026, she was living with the long-term effects of surgery, chemotherapy, radiation, and ongoing EGFR-targeted therapy, while also managing the emotional and financial burden of cancer as a single parent.

The Patient StoryRead more →

Stage IV Non-Small Cell Lung Cancer: Natalie's Patient Story

Patient Info: Natalie, Female, Under 40 | Stage IV

Metastatic Site: Spine

Natalie was living with Stage IV NSCLC after a double lung transplant gave her new lung function, but cancer later appeared in the spine and required renewed chemotherapy and radiation.

The Patient StoryRead more →

Stage IIB lung adenocarcinoma: pembrolizumab-associated psoriasiform dermatitis resolved after stopping therapy

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: PD-L1 status not reported in the available case text

Over 3 years of follow-up after stopping pembrolizumab, the psoriasiform dermatitis resolved completely and lung adenocarcinoma remained stable without radiologic or serologic recurrence.

PubMed CentralRead more →

Stage IA2 squamous lung cancer: lung-sparing segmentectomy after COPD optimization

Patient Info: Anonymized, Male, 70+

Biomarkers: Squamous lung cancer markers present; PD-L1 TPS 10%, EGFR IHC present

At 18 months after lung-sparing VATS segmentectomy, he had good quality of life, no dyspnea or chronic cough, and surveillance imaging showed no recurrence.

PubMed CentralRead more →

Targeted therapy made Stage III ALK-positive lung cancer operable

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ALK-positive; PD-L1 high

Surgery found no residual cancer, and follow-up scans showed no recurrence through 15 months.

PubMed CentralRead more →

Stage IV EGFR-positive lung cancer treated for nearly 5 years before progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR L858R mutation

Metastatic Site: liver

The cancer later progressed despite chemotherapy, and he died from lung cancer 4 years and 8 months after diagnosis.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Maggie's Patient Story

Patient Info: Maggie, Female, 60s | Stage IV

Biomarkers: EGFR mutation; MET amplification resistance mutation; MET overexpression

Metastatic Site: Brain

Maggie initially reached no evidence of disease on EGFR-targeted therapy, but later had repeated progression, including MET-amplification resistance and MET overexpression, requiring SBRT, a clinical trial, chemotherapy, and later-line targeted treatment.

The Patient StoryRead more →

Stage IV small-cell lung cancer with hepatic metastases: serplulimab stopped after VKH-like uveitis

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: No molecular biomarkers reported

Metastatic Site: liver

Serplulimab was discontinued after VKH-like uveitis; oral prednisone improved vision, but the case did not report a definitive cancer-response outcome after immunotherapy interruption.

PubMed CentralRead more →

Pulmonary nocardiosis that mimicked lung cancer in a man with COPD

Patient Info: Anonymized, Male, 70+

Biomarkers: Not applicable; malignancy not found

The lung lesions were ultimately attributed to pulmonary nocardiosis rather than cancer. Symptoms, inflammatory markers, and CT findings improved after pathogen-directed antibiotics, and the patient was discharged stable with follow-up arranged.

PubMed CentralRead more →

Stage IV pleomorphic lung cancer complicated by esophageal invasion and severe infection

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: BRAF ; PD-L1 high

Metastatic Site: pleura|peritoneum|bone

He died 21 days after admission from respiratory failure caused by advanced lung cancer complicated by severe infection and aspiration.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Clara's Patient Story

Patient Info: Clara, Female, Under 40 | Stage IV

Biomarkers: ALK-positive / ALK-rearranged after repeat Tempus testing

Metastatic Site: Pelvis; spleen

As of February 2026, ALK-targeted therapy had improved Clara’s symptoms enough that she no longer needed a walker or cane, and upcoming scans would determine whether pelvic tumor surgery remained an option.

The Patient StoryRead more →

Stage I EGFR Lung Cancer: Shira's Survivor Story

Patient Info: Shira, Female | Stage I

Biomarkers: EGFR exon 20 insertion

Shira had Stage IB lung cancer detected early through imaging and treated with surgery alone. Her tumor was later categorized as low risk of recurrence, and she described herself as cancer-free as of February 2026.

The Patient StoryRead more →

Stage IVB lung adenocarcinoma with severe immune-related complications

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 TPS 20%; BRAF mutation

Metastatic Site: left supraclavicular fossa, left axilla, right hilum,…

The patient had an initial partial response to ipilimumab/nivolumab but developed severe immune-related pneumonitis, thrombocytopenia, and aplastic anemia. Cytopenias recovered with eltrombopag, but lung cancer later relapsed with carcinomatous meningitis, and he died 20 months after diagnosis.

PubMed CentralRead more →

Stage IV ROS1 Lung Cancer: Phil's Patient Story

Patient Info: Phil, Male, 60s | Stage IV

Biomarkers: ROS1 mutation

Metastatic Site: Lymph nodes; other lung

Phil was living with incurable Stage IV ROS1-positive lung cancer. After initial chemotherapy, a ROS1-targeted pill worked for about 2 years, and he later continued on a Mass General clinical-trial treatment with follow-up every 3 months.

The Patient StoryRead more →

Extensive-stage small-cell lung cancer with malignant superior vena cava syndrome

Patient Info: Anonymized, Male, 60s

After superior vena cava stenting, facial and upper-extremity edema improved, he was discharged on hospital day 7, and he lived at home without recurrent SVCS symptoms until death from worsening lung cancer about 2 months later.

PubMed CentralRead more →

Prior Stage IA lung adenocarcinoma with fungal airway disease mimicking recurrence

Patient Info: Anonymized, Female, 70+ | Stage I

Her prior Stage IA lung adenocarcinoma was surgically treated without adjuvant therapy, and later pulmonary lesions were attributed to allergic bronchopulmonary mycosis rather than cancer recurrence; symptoms and imaging improved after antifungal and inhaled therapy.

PubMed CentralRead more →

Pulmonary epithelioid hemangioendothelioma with complete response after neoadjuvant therapy

Patient Info: Anonymized, Male, 60s

Biomarkers: WWTR1-CAMTA1 fusion; vascular markers supported epithelioid hemangioendothelioma; lung cancer markers were absent.

The patient achieved radiographic disappearance of the lung tumor after neoadjuvant paclitaxel/carboplatin plus bevacizumab. Surgery then showed no residual tumor and lymph nodes were negative; CT follow-up through April 2024 showed no recurrence.

PubMed CentralRead more →

Locally advanced lung adenocarcinoma: neoadjuvant treatment, surgery, and fistula repair

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Three months after reconstruction for postoperative esophagopleural fistula, her nutritional status had improved and esophagogram showed no anastomotic leak; long-term lung cancer control was not reported.

PubMed CentralRead more →

Stage I Lung Cancer: Taylor's Survivor Story

Patient Info: Taylor, Female, Under 40 | Stage I

Taylor had a Stage IB 4 cm lung carcinoid tumor removed surgically with clean margins at age 21. She did not need chemotherapy or radiation and was 18 years post-diagnosis as of February 2026.

The Patient StoryRead more →